BioCardia CEO buys 1,900 shares in open market

Q: What did BioCardia (BCDA) CEO Peter Altman report in this Form 4?

Peter Altman reported purchasing 1,900 shares of BioCardia common stock on August 13, 2026. The open-market transaction was executed at a weighted average price of $0.92 per share, increasing his direct holdings to 375,785 shares after the trade.

Q: How many BioCardia (BCDA) shares does Peter Altman own after this Form 4 transaction?

After the reported purchase, Peter Altman directly owns 375,785 shares of BioCardia common stock. This figure reflects his post-transaction direct holdings as disclosed, and does not include any additional derivative securities, which were not reported in this filing.

Q: Was the BioCardia (BCDA) CEO’s Form 4 trade made under a Rule 10b5-1 plan?

The filing indicates the trade was not made under a Rule 10b5-1 trading plan, as the related checkbox was not selected. The purchase therefore appears as a discretionary open-market transaction based on the information disclosed in the Form 4.

Q: What type of transaction is reported in the BioCardia (BCDA) Form 4?

The Form 4 reports a code P transaction, described as a purchase in an open market or private transaction. In this case, 1,900 shares of common stock were acquired, with the price reported on a weighted average per-share basis.

BioCardia, Inc. director and President & CEO Peter Altman purchased 1,900 shares of common stock on August 13, 2026 in an open-market transaction at a weighted average price of $0.92 per share, with individual trade prices ranging from $0.89 to $0.95.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BioCardia, Inc. director and President & CEO Peter Altman purchased 1,900 shares of common stock on August 13, 2026 in an open-market transaction at a weighted average price of $0.92 per share, with individual trade prices ranging from $0.89 to $0.95. Following this purchase, he directly holds 375,785 shares of BioCardia common stock. The transaction was not reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Buyer: 1,900 shares

Net Buy 1 txn

Insider Altman Peter

Role President and CEO

Bought 1,900 shs ($2K)

Type	Security	Shares	Price	Value
Purchase	Common Stock ^F1	1,900	$0.92	$2K

Holdings After Transaction: Common Stock — 375,785 shares (Direct)

Footnotes (1)

F1. This transaction was executed in multiple trades ranging from $0.89 to $0.95 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

Key Figures

Shares purchased: 1,900 shares Weighted average purchase price: $0.92 per share Post-transaction holdings: 375,785 shares +1 more

4 metrics

Shares purchased 1,900 shares Common stock bought on August 13, 2026

Weighted average purchase price $0.92 per share Open-market purchase of 1,900 shares

Post-transaction holdings 375,785 shares Direct ownership after the reported purchase

Trade price range $0.89–$0.95 per share Range of individual trades included in weighted average

Key Terms

Rule 10b5-1 trading plan, weighted average per share, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction was not reported as made under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"transaction code description is Purchase in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioCardia (BCDA) CEO Peter Altman report in this Form 4?

Peter Altman reported purchasing 1,900 shares of BioCardia common stock on August 13, 2026. The open-market transaction was executed at a weighted average price of $0.92 per share, increasing his direct holdings to 375,785 shares after the trade.

At what prices did the BioCardia (BCDA) Form 4 trades occur?

The 1,900 BioCardia shares were bought at prices ranging from $0.89 to $0.95 per share. The Form 4 reports a weighted average purchase price of $0.92 per share, with the insider offering to provide detailed trade-by-trade pricing information upon request.

How many BioCardia (BCDA) shares does Peter Altman own after this Form 4 transaction?

After the reported purchase, Peter Altman directly owns 375,785 shares of BioCardia common stock. This figure reflects his post-transaction direct holdings as disclosed, and does not include any additional derivative securities, which were not reported in this filing.

Was the BioCardia (BCDA) CEO’s Form 4 trade made under a Rule 10b5-1 plan?

The filing indicates the trade was not made under a Rule 10b5-1 trading plan, as the related checkbox was not selected. The purchase therefore appears as a discretionary open-market transaction based on the information disclosed in the Form 4.

What type of transaction is reported in the BioCardia (BCDA) Form 4?

The Form 4 reports a code P transaction, described as a purchase in an open market or private transaction. In this case, 1,900 shares of common stock were acquired, with the price reported on a weighted average per-share basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/13/2026 - 05:43 PM Accepted by SEC EDGAR 08/13/2026 - 05:43 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Altman Peter

(Last)

(First)

(Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE

CALIFORNIA

94085

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/13/2026		P		1,900⁽¹⁾	A	$0.92⁽¹⁾	375,785	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed in multiple trades ranging from $0.89 to $0.95 per share. The price reported above reflects the weighted average per share sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer, full information regarding the number shares purchased at each separate price.

	/s/ David McClung, by power of attorney	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR